Bragar Eagel & Squire, P.C. Reminds Investors That Class

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
40
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Welbilt, AxoGen, Markel, and Maxar and Encourages Investors to Contact the Firm

NEW YORK, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Welbilt, Inc., AxoGen, Inc., Markel Corporation, and Maxar Technologies Ltd.  Stockholders have until the deadlines listed below to petition the court to serve as lead plaintiff.  Additional information about each case can be found at the link provided.

Welbilt, Inc. (NYSE: WBT)

Class Period: February 24, 2017 - November 2, 2018

Lead Plaintiff Deadline: February 11, 2019

The complaint alleges that throughout the class period Welbilt made materially false and/or misleading statements and/or failed to disclose that: (1) the company lacked effective internal control over financial reporting; (2) the company was incorrectly recording the tax basis of foreign subsidiaries and the amortization of their intangible assets; and (3) as a result of the foregoing, defendants’ statements about Welbilt’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

To learn more about the Welbilt class action go to:  https://bespc.com/wbt/ .

AxoGen, Inc. (NASDAQ: AXGN)

Class Period: August 7, 2017 - December 18, 2018

Lead Plaintiff Deadline: March 11, 2019

The complaint alleges that throughout the class period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects.  Specifically, the complaint alleges that defendants failed to disclose: (1) that the company aggressively increased prices to mask lower sales; (2) that the company’s pricing alienated customers and threatened the company’s future growth; (3) that ambulatory surgery centers form a significant part of the market for the company’s products; (4) that such centers were especially sensitive to price increases; (5) that the company was dependent on a small number of surgeons whom the company paid to generate sales; (6) that the company’s consignment model for inventory was reasonably likely to lead to channel stuffing; (7) that the company offered purchase incentives to sales representatives to encourage channel stuffing; (8) that the company’s sales representatives were encouraged to backdate revenue to artificially inflate metrics; (9) that the company lacked adequate internal controls to prevent such channel stuffing and backdating of revenue; (10) that the company’s key operating metrics, such as number of active accounts, were overstated; and (11) that, as a result of the foregoing, Defendants’ positive statements about the company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

To learn more about the AxoGen class action go to: http://bespc.com/axgn/ .

Markel Corporation (NYSE: MKL)

Class Period: July 26, 2017 - December 6, 2018

Lead Plaintiff Deadline: March 12, 2019

The complaint alleges that throughout the class period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects.  Specifically, the complaint alleges that defendants failed to disclose to investors: (1) that the company’s subsidiaries did not appropriately record loss reserves; (2) that, as a result, the loss reserves would need to be adjusted and/or restated; (3) that these misleading accounting practices would lead to regulatory scrutiny and financial loss to investors; and (4) that, as a result of the foregoing, defendant’s positive statements about the company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

To learn more about the Markel class action go to: http://bespc.com/mkl/ .

Maxar Technologies Ltd. (NYSE: MAXR)

Class Period: March 29, 2018 - January 7, 2019

Lead Plaintiff Deadline: March 15, 2019

The complaint alleges that throughout the class period defendants made materially false and misleading statements regarding the company’s business, operational, and compliance policies.  Specifically, the complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that: (1) Maxar improperly inflated the value of its intangible assets, among other accounting improprieties; (2) Maxar’s highly-valued WorldView-4 was equipped with CMGs that were faulty and/or ill-suited for their designed and intended purpose; and (3) as a result, Maxar’s public statements were materially false and misleading at all relevant times.

To learn more about the Maxar class action go to: http://bespc.com/maxr/ .

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation.  For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com .  Attorney advertising.  Prior results do not guarantee similar outcomes. 

Contacts

Bragar Eagel & Squire, P.C. Brandon Walker, Esq. Melissa Fortunato, Esq. (212) 355-4648 investigations@bespc.com www.bespc.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Protecting Teeth: Insights from Endodontist Dr. Joubert

Updated Category News Views 7

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 4

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PureHealth's Acid Reflux Solutions: An Investor's Insight

Updated Category News Views 3

Digestive Wellness: The Emerging Opportunity Some days, it feels like everybody's got a gripe about their gut. You nod along at the lunch counter, folks buzzing about digestive this and acid that. But when PureHealth Research pops up with their fancy supplements, well, even the stock market's noisier nonsense starts sounding a bit quieter. They're banking big on the...

Continue Reading
New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Updated Category News Views 5

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Continue Reading
Ajman Spotlights Tourism at Arabian Travel Market 2026

Updated Category News Views 3

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 7

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
SMPL Faces Legal Drama: What Investors Need to Know

Updated Category News Views 5

Investors Swim Against the Current With SMPL Picture this: You’re sipping your morning coffee, glancing through stocks, only to choke on your bagel when The Simply Good Foods Company (NASDAQ: SMPL) pops up with some less-than-palatable news. A class action is brewing, shouting out to investors who took the bait from October 24, 2024, to April 8, 2026. If you’re one of...

Continue Reading
Damp or Dry: The Battle for Healthy Air in Colorado

Updated Category News Views 5

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 5

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
D-Wave Faces Legal Questions After CFO Exit and Losses

Updated Category News Views 3

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Continue Reading

Top 5 Most Recently Viewed Articles

New Oriental Reports Major Financial Growth for Latest Quarter

Updated Category News Views 103

New Oriental Education & Technology Group Inc. Financial Results Overview New Oriental Education & Technology Group Inc. (NYSE: EDU) has recently unveiled its unaudited financial results for the second fiscal quarter ended November 30. This marks a significant period in the company's journey, highlighting an impressive rise in net revenues and overall financial...

Continue Reading
Continued Confidence Among CEOs and Investors in 2026 Growth

Updated Category News Views 137

Continued Confidence Among CEOs and Investors in 2026 Growth Recent insights reveal that CEO and investor expectations for growth, mergers and acquisitions (M&A), and hiring are notably high. However, these aspirations come with caution, spurred by challenges related to global trade, geopolitical uncertainties, and rapid technological advancements. High Expectations for...

Continue Reading
Understanding S&P 500 E-Mini Trends: Are We in for a Shift?

Updated Category News Views 201

The S&P 500 E-Mini futures market saw quite the ruckus back then. As traders scanned the weekly charts, smaller candlestick patterns hinted at a shift in momentum that got everyone on edge. They had their eyes glued to that 20-week exponential moving average (EMA)—a critical support level that bulls hoped would come through for them as they scrambled for a double-bottom...

Continue Reading
Understanding Recent Legal Challenges Facing Nutex Health Inc.

Updated Category News Views 127

The Current Legal Landscape for Nutex Health Inc. Nutex Health Inc. is currently facing significant legal challenges that have sparked interest among its investors and market watchers. These challenges are crucial to understanding the company’s financial health and future prospects. Recently, a class action lawsuit was announced against the Company, raising concerns...

Continue Reading
BellRing Brands Faces Legal Scrutiny: Investors Encouraged to Engage

Updated Category News Views 120

Introduction to the Investigation Bragar Eagel & Squire, P.C., a respected law firm focused on investor rights, is currently investigating potential claims against BellRing Brands Inc. (BRBR). This inquiry aims to determine whether the company violated federal securities laws or engaged in unlawful business practices, impacting their shareholders. Investors who have...

Continue Reading